MDPI and ACS Style
Kınıkoğlu, O.; Odabas, H.; Altıntaş, Y.E.; Yıldız, A.; Çakan, B.; Akdağ, G.; Yıldırım, S.; Bal, H.; Kaya, T.; Tünbekici, S.;
et al. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Medicina 2024, 60, 951.
https://doi.org/10.3390/medicina60060951
AMA Style
Kınıkoğlu O, Odabas H, Altıntaş YE, Yıldız A, Çakan B, Akdağ G, Yıldırım S, Bal H, Kaya T, Tünbekici S,
et al. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Medicina. 2024; 60(6):951.
https://doi.org/10.3390/medicina60060951
Chicago/Turabian Style
Kınıkoğlu, Oğuzcan, Hatice Odabas, Yunus Emre Altıntaş, Anıl Yıldız, Burçin Çakan, Goncagül Akdağ, Sedat Yıldırım, Hamit Bal, Tuğba Kaya, Salih Tünbekici,
and et al. 2024. "Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer" Medicina 60, no. 6: 951.
https://doi.org/10.3390/medicina60060951